Plus Therapeutics Presents New Phase 2 ReSPECT-GBM Trial Data at 2024 CNS Meeting

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company specializing in radiotherapeutics for central nervous system (CNS) cancers, is set to reveal significant advancements in its treatment program for recurrent glioblastoma (rGBM) at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting. This event will take place from September 28 to October 2 in Houston, Texas.

The presentation, titled "Treatment of Recurrent Glioblastoma (rGBM) via Convection Enhanced Delivery (CED) with Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL): ReSPECT-GBM Phase 2 Trial Update," will be delivered by Dr. John Floyd, an Associate Professor and Chairman of Neurosurgery at UT Health Science San Antonio. This session is scheduled for September 30, 2024, from 7:00-8:30 a.m. CDT at the George R. Brown Convention Center.

Recurrent glioblastoma, a highly aggressive form of brain cancer, impacts around 15,000 individuals each year in the United States. It is known for its poor prognosis, with an average life expectancy of less than two years, a one-year survival rate of 40%, and a five-year survival rate of just 5%. Current treatments for rGBM are limited in efficacy and often come with severe side effects, restricting their prolonged use. Approximately 90% of patients experience a recurrence of the tumor at or near the original site, and there are no FDA-approved treatments that significantly extend survival in these cases.

Rhenium (186Re) Obisbemeda represents a novel approach in treating CNS tumors. This injectable radiotherapy is formulated to deliver high-dose radiation directly to the tumor, aiming to optimize patient outcomes by minimizing off-target effects and improving the potency of the treatment. The unique properties of Rhenium-186, which include a short half-life, beta energy for effectively targeting cancer cells, and gamma energy for real-time imaging, make it particularly suited for CNS applications.

The ReSPECT-GBM clinical trial, which is supported by the National Cancer Institute (NCI), is evaluating the effectiveness of Rhenium (186Re) Obisbemeda for treating recurrent glioblastoma. Additionally, the ReSPECT-LM trial, funded by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), is investigating its use in treating leptomeningeal metastases.

Convection Enhanced Delivery (CED) is a method used to improve the precision of drug delivery to brain tumors. This technique involves minimally invasive surgery to place small catheters directly into the tumor, enabling the targeted administration of therapeutics.

Plus Therapeutics is at the forefront of developing targeted radiotherapeutics for CNS cancers through innovative image-guided beta radiation and precise drug delivery systems. The company is advancing a promising pipeline, with lead programs focusing on recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics has established strategic partnerships to facilitate the development, manufacturing, and future commercialization of its products.

Operating in key cancer research hubs, including Austin and San Antonio, Texas, Plus Therapeutics is guided by a committed leadership team dedicated to improving clinical outcomes for patients with challenging CNS cancers.